Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of PUL-042 Inhalation Solution in Reducing Lower Respiratory Tract Complications in Patients With Hematologic Malignancies and Recipients of Hematopoietic Stem Cell Transplantation (HSCT) With Documented Viral Infections With PIV, hMPV or RSV

NCT06665100 is registered in ClinicalTrials.gov with Pulmotect, Inc. as lead sponsor.

NCT NCT06665100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06665100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of PUL-042 Inhalation Solution in Reducing Lower Respiratory Tract Complications in Patients With Hematologic Malignancies and Recipients of Hematopoietic Stem Cell Transplantation (HSCT) With Documented Viral Infections With PIV, hMPV or RSV
Lead sponsor
Pulmotect, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
June 27, 2025
Completion date
May 31, 2027
Enrollment
100 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies, hematopoietic stem cell transplant (hsct)